Navigation Links
Cephalon Quarterly Conference Call Invitation
Date:6/30/2009

Second Quarter 2009 Earnings Conference Call Tuesday, August 4, 2009, 5:00 p.m. U.S. EDT

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on Tuesday, August 4, 2009.

August 4, 2009 Schedule

    4:10 p.m. EDT   Q2 2009 results will be distributed by PRNewswire
    4:50 p.m. EDT   To participate in the conference call, dial 913-312-0379
                    and refer to Conference Code Number 1696714

    5:00 p.m. EDT   Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on the "Investors" tab then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, August 11, 2009. To listen to the audio replay, dial 719-457-0820 and use the Conference Code Number 1696714.

Additional information presented on the conference call may be made available on the Investor page of the company's website.

    Contact: Robert S. (Chip) Merritt
    610-738-6376
    cmerritt@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
2. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
3. Cephalons New Product Launches Pace Record 2008 Sales
4. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
5. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon Reports Another Strong Quarter
9. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
10. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
11. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... University (NTU) signed the Memorandum of Understanding in ... (CNRS) and the Thales Group of Companies to ... parties are meeting again in Singapore to inaugurate ... , Located at the Research Techno Plaza, ... in science and technology to develop innovations in ...
(Date:12/16/2009)... Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life ... policy, to families nationwide and internationally, said today ... total of $1.4 million so far in the ... for the year now tops $10 million. ,, ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Calif., Dec. 15 Epeius Biotechnologies Corporation, ... genetic medicine, gained international validation of the cutting-edge ... , when scientists around the world rediscovered the ... major locus of cancer pathogenesis and disease progression, ... Recently, scientists at the NIH National Cancer Institute ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... FL on Thursday, May 1,2008 at 9:20 a.m. ET ... Executive Officer of Amylin Pharmaceuticals, will be providing a,corporate ... be webcast, and a,recording will be made available following ...
... America (Nasdaq: DCAI ) announced today that it ... 7, 2008, after the close of the,market. The company ... first quarter 2008 earnings release the following morning, May ... participating in the May 8, 2008 conference call,may dial ...
... Congenital Heart Disease Database and, the Further Transition ... ... April 25 VentriPoint(TM) Diagnostics,Ltd. (TSX: VPT) today announced ... with the University of Washington to,collaborate on projects that ...
Other Biology Technology:Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2VentriPoint, University of Washington Sign Research and Technology Development Agreement 2
(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
(Date:12/16/2009)... REDWOOD SHORES, Calif. and PALM HARBOR, Fla., ... ("CIC") (OTC Bulletin Board: CICI), a leading ... process automation in the financial industry* and ... and Docubase Systems Inc. ("Docubase"), a leading ... announced today that they have entered an ...
(Date:12/16/2009)... -- National Instruments (Nasdaq: NATI ), ... and DENSO Robotics, a leader and pioneer ... announced their collaboration to integrate NI measurement ... The collaboration increases productivity and performance in ... In today,s trend toward high-mix, low-volume manufacturing, ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5AHA Board Elects John Bluford Chair Elect Designate 52607 1AHA Board Elects John Bluford Chair Elect Designate 52607 2AHA Board Elects John Bluford Chair Elect Designate 52607 3Immucor Announces Fiscal Fourth Quarter Results 52606 1Immucor Announces Fiscal Fourth Quarter Results 52606 2Immucor Announces Fiscal Fourth Quarter Results 52606 3Immucor Announces Fiscal Fourth Quarter Results 52606 4Immucor Announces Fiscal Fourth Quarter Results 52606 5Immucor Announces Fiscal Fourth Quarter Results 52606 6Immucor Announces Fiscal Fourth Quarter Results 52606 7Immucor Announces Fiscal Fourth Quarter Results 52606 8Immucor Announces Fiscal Fourth Quarter Results 52606 9Immucor Announces Fiscal Fourth Quarter Results 52606 10Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 13172 1Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 13172 2
... dramatic reduction in the impact of malaria is in prospect ... Guinea early next year. Success in the trial would open ... with this debilitating and often fatal disease - over 500,000,000 ... Medical Research is collaborating with the Papua New Guinea Institute ...
... Francisco VA Medical Center (SFVAMC) and the University of ... with lymphocytic bronchitis, which is thought to lead to ... failure of transplanted lungs. , The researchers hope their ... more accurate standard test for chronic lung rejection, as ...
... number of living Florida panthers has grown from a previously ... of a controversial breeding effort to improve the genetic health ... assessment. , Hybrid kittens born to panthers brought into the ... of becoming adults as do purebred ones," reports a paper ...
Other Biology News:Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 3
Request Info...
... The Nick Translation System is ideal for ... The Nick Translation System: Provides five ... nucleotide incorporation Yields >10 8 ... control DNA to monitor the performance of ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: